CAR T-cell therapy for leukemia leads to remissions in clinical trial
Researchers at Fred Hutchinson Cancer Research Center showcased about seventy percent of patients with the most common adult leukemia had their tumors shrink or vanish following an experimental chimeric antigen receptor (CAR) T-cell immunotherapy.
The researchers also found that measuring genetic traces of cancer cells taken from bone marrow biopsies might be a better indicator of prognosis than the standard lymph knot scan.
The Journal of Clinical Oncology published the results online July seventeen of the Phase 1/Two clinical trial, which included twenty four patients with chronic lymphocytic leukemia (CLL) who had failed other treatments. Most of the patients had seen their cancer progress despite treatment with ibrutinib, a targeted cancer drug approved in two thousand fourteen for CLL by the U.S. Food and Drug Administration.
This history placed them in a high-risk group that was found in previous studies to have brief survival with standard therapies.
“It was not known whether CAR T-cells could be used to treat these high risk CLL patients,” said lead author Dr. Cameron Turtle, an immunotherapy researcher at Fred Hutch. “Our investigate shows that CD19 CAR T-cells are a very promising treatment for CLL patients who have failed ibrutinib.”
CD19 CAR T-cells are a type of immunotherapy in which a patient’s T cells are extracted from their blood and modified in a lab to recognize CD19, a target on the surface of leukemia cells. The engineered T cells are then infused back into the patient where they multiply and hunt down and kill cancer cells.
In CLL, bone marrow makes too many abnormal lymphocytes, which are a type of white blood cell. The American Cancer Society estimates that in the U.S., there will be about 20,000 fresh cases and Four,600 deaths from CLL in 2017. Tests of blood, bone marrow and lymph nodes—where lymphocytes congregate to fight infection—reveal the disease.
The twenty four patients participating in the investigate ranged in age from forty to seventy three years, with a median age of 61. They had received a median of five other therapies with as few as three and as many as nine.
Researchers found that seventeen out of twenty four (71 percent) of patients witnessed their tumors shrink or vanish following CAR T-cell therapy using the standard measure of lymph knot size by CT scans four weeks after treatment.
Of side effects of CAR-T cell therapy, twenty of the twenty four patients—83 percent—experienced cytokine release syndrome (grade 1-2, eighteen patients; grade Four, one patient; grade Five, one patient) and eight patients (33 percent) developed neurotoxicity (grade Three, five patients; grade Five, one patient). For the most part the side effects were reversible, but two patients had side effects severe enough to require being admitted to the intensive care unit and one of those patients died.
(An earlier report on trial results was introduced by Turtle in December at the American Society of Hematology annual meeting.)
The fresh paper expands on the measures used to indicate whether the CAR T-cell treatment is working.
To take a closer look to see if any cancer cells remained after treatment, the research team analyzed samples taken from some of the patients’ bone marrow four weeks after the CAR T-cell infusion. The team used a genetic test called IGH deep sequencing, which is akin to a bar code and enables researchers to track cancer cells in the figure.
Turtle and his collaborators did the sequencing analysis in twelve of the patients. Seven of the twelve patients had no malignant copies. All patients without malignant copies were alive and free of disease at a median follow-up of 6.6 months after CAR T-cell infusion.
Compared with the CT scans, having no malignant gene sequences in bone marrow following CAR T-cell therapy was a better predictor of the cancer staying at bay—known as “progression-free survival,” the researchers found.
The examine is the very first to suggest that deep sequencing might be a superior measure for predicting outcomes four weeks after CAR T-cell therapy for CLL.
Provided by: Fred Hutchinson Cancer Research Center
Explore further
CD19-targeting CAR T-cell immunotherapy yields high responses in treatment-resistant CLL
In a petite, early phase trial, a high percentage of patients who had weakened most traditional treatments for chronic lymphocytic leukemia eyed their tumors shrink or even vanish after an infusion of a very targeted, .
Personalized cell therapy combination achieves finish remission in CLL patients
Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to accomplish remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to fresh .
Immunotherapy shows promise in preventing leukemia relapse
Fred Hutchinson Cancer Research Center announced promising results from an early trial in which patients with high-risk acute myeloid leukemia received genetically engineered immune cells. Of the twelve AML patients who received .
CAR T-Cell therapy sends numerous myeloma into lasting remission
In an early clinical trial, thirty three out of thirty five (94%) patients had clinical remission of numerous myeloma upon receiving a fresh type of immunotherapy ? chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or .
Probe shows promising clinical activity
Immune cellular therapy is a promising fresh area of cancer treatment. Anti-cancer therapeutics, such as chimeric antigen receptor (CAR) modified T cells, can be engineered to target tumor-associated antigens to attack and .
Triple immunotherapy for uncommon skin cancer shows promise in puny, early-stage trial
Three out of four patients treated with an experimental combination of three different therapies for the infrequent skin cancer known as Merkel cell carcinoma are in accomplish remission following the treatment, according to examine .
Medical Xpress: CAR T-cell therapy for leukemia leads to remissions in clinical trial
CAR T-cell therapy for leukemia leads to remissions in clinical trial
Researchers at Fred Hutchinson Cancer Research Center showcased about seventy percent of patients with the most common adult leukemia had their tumors shrink or vanish following an experimental chimeric antigen receptor (CAR) T-cell immunotherapy.
The researchers also found that measuring genetic traces of cancer cells taken from bone marrow biopsies might be a better indicator of prognosis than the standard lymph knot scan.
The Journal of Clinical Oncology published the results online July seventeen of the Phase 1/Two clinical trial, which included twenty four patients with chronic lymphocytic leukemia (CLL) who had failed other treatments. Most of the patients had seen their cancer progress despite treatment with ibrutinib, a targeted cancer drug approved in two thousand fourteen for CLL by the U.S. Food and Drug Administration.
This history placed them in a high-risk group that was found in previous studies to have brief survival with standard therapies.
“It was not known whether CAR T-cells could be used to treat these high risk CLL patients,” said lead author Dr. Cameron Turtle, an immunotherapy researcher at Fred Hutch. “Our examine shows that CD19 CAR T-cells are a very promising treatment for CLL patients who have failed ibrutinib.”
CD19 CAR T-cells are a type of immunotherapy in which a patient’s T cells are extracted from their blood and modified in a lab to recognize CD19, a target on the surface of leukemia cells. The engineered T cells are then infused back into the patient where they multiply and hunt down and kill cancer cells.
In CLL, bone marrow makes too many abnormal lymphocytes, which are a type of white blood cell. The American Cancer Society estimates that in the U.S., there will be about 20,000 fresh cases and Four,600 deaths from CLL in 2017. Tests of blood, bone marrow and lymph nodes—where lymphocytes congregate to fight infection—reveal the disease.
The twenty four patients participating in the examine ranged in age from forty to seventy three years, with a median age of 61. They had received a median of five other therapies with as few as three and as many as nine.
Researchers found that seventeen out of twenty four (71 percent) of patients spotted their tumors shrink or vanish following CAR T-cell therapy using the standard measure of lymph knot size by CT scans four weeks after treatment.
Of side effects of CAR-T cell therapy, twenty of the twenty four patients—83 percent—experienced cytokine release syndrome (grade 1-2, eighteen patients; grade Four, one patient; grade Five, one patient) and eight patients (33 percent) developed neurotoxicity (grade Trio, five patients; grade Five, one patient). For the most part the side effects were reversible, but two patients had side effects severe enough to require being admitted to the intensive care unit and one of those patients died.
(An earlier report on trial results was introduced by Turtle in December at the American Society of Hematology annual meeting.)
The fresh paper expands on the measures used to indicate whether the CAR T-cell treatment is working.
To take a closer look to see if any cancer cells remained after treatment, the research team analyzed samples taken from some of the patients’ bone marrow four weeks after the CAR T-cell infusion. The team used a genetic test called IGH deep sequencing, which is akin to a bar code and enables researchers to track cancer cells in the assets.
Turtle and his collaborators did the sequencing analysis in twelve of the patients. Seven of the twelve patients had no malignant copies. All patients without malignant copies were alive and free of disease at a median follow-up of 6.6 months after CAR T-cell infusion.
Compared with the CT scans, having no malignant gene sequences in bone marrow following CAR T-cell therapy was a better predictor of the cancer staying at bay—known as “progression-free survival,” the researchers found.
The investigate is the very first to suggest that deep sequencing might be a superior measure for predicting outcomes four weeks after CAR T-cell therapy for CLL.
Provided by: Fred Hutchinson Cancer Research Center
Explore further
CD19-targeting CAR T-cell immunotherapy yields high responses in treatment-resistant CLL
In a petite, early phase trial, a high percentage of patients who had tired most traditional treatments for chronic lymphocytic leukemia spotted their tumors shrink or even vanish after an infusion of a very targeted, .
Personalized cell therapy combination achieves accomplish remission in CLL patients
Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to accomplish remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to fresh .
Immunotherapy shows promise in preventing leukemia relapse
Fred Hutchinson Cancer Research Center announced promising results from an early trial in which patients with high-risk acute myeloid leukemia received genetically engineered immune cells. Of the twelve AML patients who received .
CAR T-Cell therapy sends numerous myeloma into lasting remission
In an early clinical trial, thirty three out of thirty five (94%) patients had clinical remission of numerous myeloma upon receiving a fresh type of immunotherapy ? chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or .
Explore shows promising clinical activity
Immune cellular therapy is a promising fresh area of cancer treatment. Anti-cancer therapeutics, such as chimeric antigen receptor (CAR) modified T cells, can be engineered to target tumor-associated antigens to attack and .
Triple immunotherapy for uncommon skin cancer shows promise in petite, early-stage trial
Three out of four patients treated with an experimental combination of three different therapies for the infrequent skin cancer known as Merkel cell carcinoma are in accomplish remission following the treatment, according to investigate .
Medical Xpress: CAR T-cell therapy for leukemia leads to remissions in clinical trial
CAR T-cell therapy for leukemia leads to remissions in clinical trial
Researchers at Fred Hutchinson Cancer Research Center displayed about seventy percent of patients with the most common adult leukemia had their tumors shrink or vanish following an experimental chimeric antigen receptor (CAR) T-cell immunotherapy.
The researchers also found that measuring genetic traces of cancer cells taken from bone marrow biopsies might be a better indicator of prognosis than the standard lymph knot scan.
The Journal of Clinical Oncology published the results online July seventeen of the Phase 1/Two clinical trial, which included twenty four patients with chronic lymphocytic leukemia (CLL) who had failed other treatments. Most of the patients had seen their cancer progress despite treatment with ibrutinib, a targeted cancer drug approved in two thousand fourteen for CLL by the U.S. Food and Drug Administration.
This history placed them in a high-risk group that was found in previous studies to have brief survival with standard therapies.
“It was not known whether CAR T-cells could be used to treat these high risk CLL patients,” said lead author Dr. Cameron Turtle, an immunotherapy researcher at Fred Hutch. “Our examine shows that CD19 CAR T-cells are a very promising treatment for CLL patients who have failed ibrutinib.”
CD19 CAR T-cells are a type of immunotherapy in which a patient’s T cells are extracted from their blood and modified in a lab to recognize CD19, a target on the surface of leukemia cells. The engineered T cells are then infused back into the patient where they multiply and hunt down and kill cancer cells.
In CLL, bone marrow makes too many abnormal lymphocytes, which are a type of white blood cell. The American Cancer Society estimates that in the U.S., there will be about 20,000 fresh cases and Four,600 deaths from CLL in 2017. Tests of blood, bone marrow and lymph nodes—where lymphocytes congregate to fight infection—reveal the disease.
The twenty four patients participating in the investigate ranged in age from forty to seventy three years, with a median age of 61. They had received a median of five other therapies with as few as three and as many as nine.
Researchers found that seventeen out of twenty four (71 percent) of patients spotted their tumors shrink or vanish following CAR T-cell therapy using the standard measure of lymph knot size by CT scans four weeks after treatment.
Of side effects of CAR-T cell therapy, twenty of the twenty four patients—83 percent—experienced cytokine release syndrome (grade 1-2, eighteen patients; grade Four, one patient; grade Five, one patient) and eight patients (33 percent) developed neurotoxicity (grade Three, five patients; grade Five, one patient). For the most part the side effects were reversible, but two patients had side effects severe enough to require being admitted to the intensive care unit and one of those patients died.
(An earlier report on trial results was introduced by Turtle in December at the American Society of Hematology annual meeting.)
The fresh paper expands on the measures used to indicate whether the CAR T-cell treatment is working.
To take a closer look to see if any cancer cells remained after treatment, the research team analyzed samples taken from some of the patients’ bone marrow four weeks after the CAR T-cell infusion. The team used a genetic test called IGH deep sequencing, which is akin to a bar code and enables researchers to track cancer cells in the figure.
Turtle and his collaborators did the sequencing analysis in twelve of the patients. Seven of the twelve patients had no malignant copies. All patients without malignant copies were alive and free of disease at a median follow-up of 6.6 months after CAR T-cell infusion.
Compared with the CT scans, having no malignant gene sequences in bone marrow following CAR T-cell therapy was a better predictor of the cancer staying at bay—known as “progression-free survival,” the researchers found.
The probe is the very first to suggest that deep sequencing might be a superior measure for predicting outcomes four weeks after CAR T-cell therapy for CLL.
Provided by: Fred Hutchinson Cancer Research Center
Explore further
CD19-targeting CAR T-cell immunotherapy yields high responses in treatment-resistant CLL
In a puny, early phase trial, a high percentage of patients who had tired most traditional treatments for chronic lymphocytic leukemia eyed their tumors shrink or even vanish after an infusion of a very targeted, .
Personalized cell therapy combination achieves accomplish remission in CLL patients
Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to accomplish remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to fresh .
Immunotherapy shows promise in preventing leukemia relapse
Fred Hutchinson Cancer Research Center announced promising results from an early trial in which patients with high-risk acute myeloid leukemia received genetically engineered immune cells. Of the twelve AML patients who received .
CAR T-Cell therapy sends numerous myeloma into lasting remission
In an early clinical trial, thirty three out of thirty five (94%) patients had clinical remission of numerous myeloma upon receiving a fresh type of immunotherapy ? chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or .
Probe shows promising clinical activity
Immune cellular therapy is a promising fresh area of cancer treatment. Anti-cancer therapeutics, such as chimeric antigen receptor (CAR) modified T cells, can be engineered to target tumor-associated antigens to attack and .
Triple immunotherapy for uncommon skin cancer shows promise in puny, early-stage trial
Three out of four patients treated with an experimental combination of three different therapies for the uncommon skin cancer known as Merkel cell carcinoma are in finish remission following the treatment, according to probe .
Medical Xpress: CAR T-cell therapy for leukemia leads to remissions in clinical trial
CAR T-cell therapy for leukemia leads to remissions in clinical trial
Researchers at Fred Hutchinson Cancer Research Center showcased about seventy percent of patients with the most common adult leukemia had their tumors shrink or vanish following an experimental chimeric antigen receptor (CAR) T-cell immunotherapy.
The researchers also found that measuring genetic traces of cancer cells taken from bone marrow biopsies might be a better indicator of prognosis than the standard lymph knot scan.
The Journal of Clinical Oncology published the results online July seventeen of the Phase 1/Two clinical trial, which included twenty four patients with chronic lymphocytic leukemia (CLL) who had failed other treatments. Most of the patients had seen their cancer progress despite treatment with ibrutinib, a targeted cancer drug approved in two thousand fourteen for CLL by the U.S. Food and Drug Administration.
This history placed them in a high-risk group that was found in previous studies to have brief survival with standard therapies.
“It was not known whether CAR T-cells could be used to treat these high risk CLL patients,” said lead author Dr. Cameron Turtle, an immunotherapy researcher at Fred Hutch. “Our probe shows that CD19 CAR T-cells are a very promising treatment for CLL patients who have failed ibrutinib.”
CD19 CAR T-cells are a type of immunotherapy in which a patient’s T cells are extracted from their blood and modified in a lab to recognize CD19, a target on the surface of leukemia cells. The engineered T cells are then infused back into the patient where they multiply and hunt down and kill cancer cells.
In CLL, bone marrow makes too many abnormal lymphocytes, which are a type of white blood cell. The American Cancer Society estimates that in the U.S., there will be about 20,000 fresh cases and Four,600 deaths from CLL in 2017. Tests of blood, bone marrow and lymph nodes—where lymphocytes congregate to fight infection—reveal the disease.
The twenty four patients participating in the examine ranged in age from forty to seventy three years, with a median age of 61. They had received a median of five other therapies with as few as three and as many as nine.
Researchers found that seventeen out of twenty four (71 percent) of patients eyed their tumors shrink or vanish following CAR T-cell therapy using the standard measure of lymph knot size by CT scans four weeks after treatment.
Of side effects of CAR-T cell therapy, twenty of the twenty four patients—83 percent—experienced cytokine release syndrome (grade 1-2, eighteen patients; grade Four, one patient; grade Five, one patient) and eight patients (33 percent) developed neurotoxicity (grade Trio, five patients; grade Five, one patient). For the most part the side effects were reversible, but two patients had side effects severe enough to require being admitted to the intensive care unit and one of those patients died.
(An earlier report on trial results was introduced by Turtle in December at the American Society of Hematology annual meeting.)
The fresh paper expands on the measures used to indicate whether the CAR T-cell treatment is working.
To take a closer look to see if any cancer cells remained after treatment, the research team analyzed samples taken from some of the patients’ bone marrow four weeks after the CAR T-cell infusion. The team used a genetic test called IGH deep sequencing, which is akin to a bar code and enables researchers to track cancer cells in the bod.
Turtle and his collaborators did the sequencing analysis in twelve of the patients. Seven of the twelve patients had no malignant copies. All patients without malignant copies were alive and free of disease at a median follow-up of 6.6 months after CAR T-cell infusion.
Compared with the CT scans, having no malignant gene sequences in bone marrow following CAR T-cell therapy was a better predictor of the cancer staying at bay—known as “progression-free survival,” the researchers found.
The explore is the very first to suggest that deep sequencing might be a superior measure for predicting outcomes four weeks after CAR T-cell therapy for CLL.
Provided by: Fred Hutchinson Cancer Research Center
Explore further
CD19-targeting CAR T-cell immunotherapy yields high responses in treatment-resistant CLL
In a puny, early phase trial, a high percentage of patients who had weary most traditional treatments for chronic lymphocytic leukemia spotted their tumors shrink or even vanish after an infusion of a very targeted, .
Personalized cell therapy combination achieves finish remission in CLL patients
Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to accomplish remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to fresh .
Immunotherapy shows promise in preventing leukemia relapse
Fred Hutchinson Cancer Research Center announced promising results from an early trial in which patients with high-risk acute myeloid leukemia received genetically engineered immune cells. Of the twelve AML patients who received .
CAR T-Cell therapy sends numerous myeloma into lasting remission
In an early clinical trial, thirty three out of thirty five (94%) patients had clinical remission of numerous myeloma upon receiving a fresh type of immunotherapy ? chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or .
Explore shows promising clinical activity
Immune cellular therapy is a promising fresh area of cancer treatment. Anti-cancer therapeutics, such as chimeric antigen receptor (CAR) modified T cells, can be engineered to target tumor-associated antigens to attack and .
Triple immunotherapy for uncommon skin cancer shows promise in puny, early-stage trial
Three out of four patients treated with an experimental combination of three different therapies for the uncommon skin cancer known as Merkel cell carcinoma are in finish remission following the treatment, according to investigate .
Medical Xpress: CAR T-cell therapy for leukemia leads to remissions in clinical trial
CAR T-cell therapy for leukemia leads to remissions in clinical trial
Researchers at Fred Hutchinson Cancer Research Center demonstrated about seventy percent of patients with the most common adult leukemia had their tumors shrink or vanish following an experimental chimeric antigen receptor (CAR) T-cell immunotherapy.
The researchers also found that measuring genetic traces of cancer cells taken from bone marrow biopsies might be a better indicator of prognosis than the standard lymph knot scan.
The Journal of Clinical Oncology published the results online July seventeen of the Phase 1/Two clinical trial, which included twenty four patients with chronic lymphocytic leukemia (CLL) who had failed other treatments. Most of the patients had seen their cancer progress despite treatment with ibrutinib, a targeted cancer drug approved in two thousand fourteen for CLL by the U.S. Food and Drug Administration.
This history placed them in a high-risk group that was found in previous studies to have brief survival with standard therapies.
“It was not known whether CAR T-cells could be used to treat these high risk CLL patients,” said lead author Dr. Cameron Turtle, an immunotherapy researcher at Fred Hutch. “Our investigate shows that CD19 CAR T-cells are a very promising treatment for CLL patients who have failed ibrutinib.”
CD19 CAR T-cells are a type of immunotherapy in which a patient’s T cells are extracted from their blood and modified in a lab to recognize CD19, a target on the surface of leukemia cells. The engineered T cells are then infused back into the patient where they multiply and hunt down and kill cancer cells.
In CLL, bone marrow makes too many abnormal lymphocytes, which are a type of white blood cell. The American Cancer Society estimates that in the U.S., there will be about 20,000 fresh cases and Four,600 deaths from CLL in 2017. Tests of blood, bone marrow and lymph nodes—where lymphocytes congregate to fight infection—reveal the disease.
The twenty four patients participating in the investigate ranged in age from forty to seventy three years, with a median age of 61. They had received a median of five other therapies with as few as three and as many as nine.
Researchers found that seventeen out of twenty four (71 percent) of patients spotted their tumors shrink or vanish following CAR T-cell therapy using the standard measure of lymph knot size by CT scans four weeks after treatment.
Of side effects of CAR-T cell therapy, twenty of the twenty four patients—83 percent—experienced cytokine release syndrome (grade 1-2, eighteen patients; grade Four, one patient; grade Five, one patient) and eight patients (33 percent) developed neurotoxicity (grade Three, five patients; grade Five, one patient). For the most part the side effects were reversible, but two patients had side effects severe enough to require being admitted to the intensive care unit and one of those patients died.
(An earlier report on trial results was introduced by Turtle in December at the American Society of Hematology annual meeting.)
The fresh paper expands on the measures used to indicate whether the CAR T-cell treatment is working.
To take a closer look to see if any cancer cells remained after treatment, the research team analyzed samples taken from some of the patients’ bone marrow four weeks after the CAR T-cell infusion. The team used a genetic test called IGH deep sequencing, which is akin to a bar code and enables researchers to track cancer cells in the bod.
Turtle and his collaborators did the sequencing analysis in twelve of the patients. Seven of the twelve patients had no malignant copies. All patients without malignant copies were alive and free of disease at a median follow-up of 6.6 months after CAR T-cell infusion.
Compared with the CT scans, having no malignant gene sequences in bone marrow following CAR T-cell therapy was a better predictor of the cancer staying at bay—known as “progression-free survival,” the researchers found.
The investigate is the very first to suggest that deep sequencing might be a superior measure for predicting outcomes four weeks after CAR T-cell therapy for CLL.
Provided by: Fred Hutchinson Cancer Research Center
Explore further
CD19-targeting CAR T-cell immunotherapy yields high responses in treatment-resistant CLL
In a petite, early phase trial, a high percentage of patients who had weary most traditional treatments for chronic lymphocytic leukemia spotted their tumors shrink or even vanish after an infusion of a very targeted, .
Personalized cell therapy combination achieves finish remission in CLL patients
Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to accomplish remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to fresh .
Immunotherapy shows promise in preventing leukemia relapse
Fred Hutchinson Cancer Research Center announced promising results from an early trial in which patients with high-risk acute myeloid leukemia received genetically engineered immune cells. Of the twelve AML patients who received .
CAR T-Cell therapy sends numerous myeloma into lasting remission
In an early clinical trial, thirty three out of thirty five (94%) patients had clinical remission of numerous myeloma upon receiving a fresh type of immunotherapy ? chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or .
Investigate shows promising clinical activity
Immune cellular therapy is a promising fresh area of cancer treatment. Anti-cancer therapeutics, such as chimeric antigen receptor (CAR) modified T cells, can be engineered to target tumor-associated antigens to attack and .
Triple immunotherapy for infrequent skin cancer shows promise in petite, early-stage trial
Three out of four patients treated with an experimental combination of three different therapies for the uncommon skin cancer known as Merkel cell carcinoma are in finish remission following the treatment, according to investigate .
Medical Xpress: CAR T-cell therapy for leukemia leads to remissions in clinical trial
CAR T-cell therapy for leukemia leads to remissions in clinical trial
Researchers at Fred Hutchinson Cancer Research Center displayed about seventy percent of patients with the most common adult leukemia had their tumors shrink or vanish following an experimental chimeric antigen receptor (CAR) T-cell immunotherapy.
The researchers also found that measuring genetic traces of cancer cells taken from bone marrow biopsies might be a better indicator of prognosis than the standard lymph knot scan.
The Journal of Clinical Oncology published the results online July seventeen of the Phase 1/Two clinical trial, which included twenty four patients with chronic lymphocytic leukemia (CLL) who had failed other treatments. Most of the patients had seen their cancer progress despite treatment with ibrutinib, a targeted cancer drug approved in two thousand fourteen for CLL by the U.S. Food and Drug Administration.
This history placed them in a high-risk group that was found in previous studies to have brief survival with standard therapies.
“It was not known whether CAR T-cells could be used to treat these high risk CLL patients,” said lead author Dr. Cameron Turtle, an immunotherapy researcher at Fred Hutch. “Our probe shows that CD19 CAR T-cells are a very promising treatment for CLL patients who have failed ibrutinib.”
CD19 CAR T-cells are a type of immunotherapy in which a patient’s T cells are extracted from their blood and modified in a lab to recognize CD19, a target on the surface of leukemia cells. The engineered T cells are then infused back into the patient where they multiply and hunt down and kill cancer cells.
In CLL, bone marrow makes too many abnormal lymphocytes, which are a type of white blood cell. The American Cancer Society estimates that in the U.S., there will be about 20,000 fresh cases and Four,600 deaths from CLL in 2017. Tests of blood, bone marrow and lymph nodes—where lymphocytes congregate to fight infection—reveal the disease.
The twenty four patients participating in the explore ranged in age from forty to seventy three years, with a median age of 61. They had received a median of five other therapies with as few as three and as many as nine.
Researchers found that seventeen out of twenty four (71 percent) of patients eyed their tumors shrink or vanish following CAR T-cell therapy using the standard measure of lymph knot size by CT scans four weeks after treatment.
Of side effects of CAR-T cell therapy, twenty of the twenty four patients—83 percent—experienced cytokine release syndrome (grade 1-2, eighteen patients; grade Four, one patient; grade Five, one patient) and eight patients (33 percent) developed neurotoxicity (grade Three, five patients; grade Five, one patient). For the most part the side effects were reversible, but two patients had side effects severe enough to require being admitted to the intensive care unit and one of those patients died.
(An earlier report on trial results was introduced by Turtle in December at the American Society of Hematology annual meeting.)
The fresh paper expands on the measures used to indicate whether the CAR T-cell treatment is working.
To take a closer look to see if any cancer cells remained after treatment, the research team analyzed samples taken from some of the patients’ bone marrow four weeks after the CAR T-cell infusion. The team used a genetic test called IGH deep sequencing, which is akin to a bar code and enables researchers to track cancer cells in the figure.
Turtle and his collaborators did the sequencing analysis in twelve of the patients. Seven of the twelve patients had no malignant copies. All patients without malignant copies were alive and free of disease at a median follow-up of 6.6 months after CAR T-cell infusion.
Compared with the CT scans, having no malignant gene sequences in bone marrow following CAR T-cell therapy was a better predictor of the cancer staying at bay—known as “progression-free survival,” the researchers found.
The explore is the very first to suggest that deep sequencing might be a superior measure for predicting outcomes four weeks after CAR T-cell therapy for CLL.
Provided by: Fred Hutchinson Cancer Research Center
Explore further
CD19-targeting CAR T-cell immunotherapy yields high responses in treatment-resistant CLL
In a puny, early phase trial, a high percentage of patients who had weary most traditional treatments for chronic lymphocytic leukemia eyed their tumors shrink or even vanish after an infusion of a very targeted, .
Personalized cell therapy combination achieves finish remission in CLL patients
Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to accomplish remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to fresh .
Immunotherapy shows promise in preventing leukemia relapse
Fred Hutchinson Cancer Research Center announced promising results from an early trial in which patients with high-risk acute myeloid leukemia received genetically engineered immune cells. Of the twelve AML patients who received .
CAR T-Cell therapy sends numerous myeloma into lasting remission
In an early clinical trial, thirty three out of thirty five (94%) patients had clinical remission of numerous myeloma upon receiving a fresh type of immunotherapy ? chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or .
Examine shows promising clinical activity
Immune cellular therapy is a promising fresh area of cancer treatment. Anti-cancer therapeutics, such as chimeric antigen receptor (CAR) modified T cells, can be engineered to target tumor-associated antigens to attack and .
Triple immunotherapy for infrequent skin cancer shows promise in petite, early-stage trial
Three out of four patients treated with an experimental combination of three different therapies for the uncommon skin cancer known as Merkel cell carcinoma are in finish remission following the treatment, according to investigate .